Chinese Journal of Cancerindexed by SCI
《癌症》杂志
BMC

About the cover
About the cover

Dec. 2016; Volume 35 Issue 12

1, On December 19, 1978, cisplatin, the "penicillin of cancer drugs", was approved for use in testicular and ovarian cancers by the U.S. Food and Drug Administration.

2, In December 1942, nitrogen mustards started to be used as an effective treatment for cancer for the treatment of lymphoma in human clinical trials, which is the beginning of the modern era of cancer chemotherapy.


Research Highlight
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Elizabeth A. Kuczynski and Robert S. Kerbel
[ Abstract  470]  [ PDF Full-text  363]   [ HTML Full-text  195]    Epub: 2016-12-26  doi: 10.1186/s40880-016-0162-7
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
Shaodong Hong and Li Zhang
[ Abstract  347]  [ PDF Full-text  375]   [ HTML Full-text  272]    Epub: 2016-12-23  doi: 10.1186/s40880-016-0163-6
Review
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics
Ilaria Fuso Nerini, Marta Cesca, Francesca Bizzaro and Raffaella Giavazzi
[ Abstract  566]  [ PDF Full-text  607]   [ HTML Full-text  604]    Epub: 2016-6-29  doi: 10.1186/s40880-016-0123-1
Editorial
Defeating cancer: the 150 most important questions in cancer research and clinical oncology
Chao-Nan Qian, Wei Zhang and Rui-Hua Xu
[ Abstract  310]  [ PDF Full-text  375]   [ HTML Full-text  294]    Epub: 2016-12-30  doi: 10.1186/s40880-016-0165-4
Original Article
Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment
Wenhua Liang, Guanzhu Shen, Yaxiong Zhang, Gang Chen, Xuan Wu, Yang Li, Anchuan Li, Shiyang Kang, Xi Yuan, Xue Hou, Peiyu Huang, Yan Huang, Hongyun Zhao, Ying Tian, Chong Zhao and Li Zhang
[ Abstract  542]  [ PDF Full-text  523]   [ HTML Full-text  189]    Epub: 2016-12-26  doi: 10.1186/s40880-016-0160-9
MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression
Run-Fen Cheng, Jian Wang, Jing-Yi Zhang, Lin Sun, Yan-Rui Zhao, Zhi-Qiang Qiu, Bao-Cun Sun and Yan Sun
[ Abstract  757]  [ PDF Full-text  1048]   [ HTML Full-text  911]    Epub: 2016-7-2  doi: 10.1186/s40880-016-0128-9
Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy
Yan-Ping Mao, Ling-Long Tang, Lei Chen, Ying Sun, Zhen-Yu Qi, Guan-Qun Zhou, Li-Zhi Liu, Li Li, Ai-Hua Lin and Jun Ma
[ Abstract  308]  [ PDF Full-text  323]   [ HTML Full-text  276]    Epub: 2016-12-30  doi: 10.1186/s40880-016-0167-2
The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis
John Zeng Hong Li, Wei Gao, Wai-Kuen Ho, Wen Bin Lei, William Ignace Wei, Jimmy Yu-Wai Chan and Thian-Sze Wong
[ Abstract  408]  [ PDF Full-text  385]   [ HTML Full-text  339]    Epub: 2016-11-20  doi: 10.1186/s40880-016-0158-3
Editorial
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Yun Leng, Lugui Qiu, Jian Hou, Yaozhong Zhao, Xuejun Zhang, Shifang Yang, Hao Xi, Zhongxia Huang, Ling Pan and Wenming Chen
[ Abstract  423]  [ PDF Full-text  473]   [ HTML Full-text  468]    Epub: 2016-9-8  doi: 10.1186/s40880-016-0140-0
Original Article
ABO blood group is a predictor of survival in patients with laryngeal cancer
Ting Jin, Pei-Jing Li, Xiao-Zhong Chen and Wei-Han Hu
[ Abstract  416]  [ PDF Full-text  477]   [ HTML Full-text  388]    Epub: 2016-10-17  doi: 10.1186/s40880-016-0152-9
New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study
Qing-Qing Cai, Li-Yang Hu, Qi-Rong Geng, Jie Chen, Zhen-Hai Lu, Hui-Lan Rao, Qing Liu, Wen-Qi Jiang, Hui-Qiang Huang, Tong-Yu Lin and Zhong-Jun Xia
[ Abstract  445]  [ PDF Full-text  524]   [ HTML Full-text  449]    Epub: 2016-9-13  doi: 10.1186/s40880-016-0150-y
Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy
Yu-Xiang He, Ying Wang, Peng-Fei Cao, Lin Shen, Ya-Jie Zhao, Zi-Jian Zhang, Deng-Ming Chen, Tu-Bao Yang, Xin-Qiong Huang, Zhou Qin, You-Yi Dai and Liang-Fang Shen
[ Abstract  485]  [ PDF Full-text  567]   [ HTML Full-text  351]    Epub: 2016-11-17  doi: 10.1186/s40880-016-0159-2
Study Protocol
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Masahito Kotaka, Ruihua Xu, Kei Muro, Young Suk Park, Satoshi Morita, Satoru Iwasa, Hiroyuki Uetake, Tomohiro Nishina, Hiroaki Nozawa, Hiroshi Matsumoto, Kentaro Yamazaki, Sae-Won Han, Wei Wang, Joong Bae Ahn, Yanhong Deng, Sang-Hee Cho, Yi Ba, Keun-Wook Lee, Tao Zhang, Taroh Satoh, Marc E. Buyse, Baek-Yeol Ryoo, Lin Shen, Junichi Sakamoto and Tae Won Kim
[ Abstract  343]  [ PDF Full-text  393]   [ HTML Full-text  275]    Epub: 2016-12-26  doi: 10.1186/s40880-016-0166-3
Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma
Lin Kong, Jing Gao, Jiyi Hu, Weixu Hu, Xiyin Guan, Rong Lu and Jiade J. Lu
[ Abstract  356]  [ PDF Full-text  332]   [ HTML Full-text  289]    Epub: 2016-12-26  doi: 10.1186/s40880-016-0164-5




CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CJC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China